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StructureHuman Equilibrative Nucleoside Transporter 1 (hENT1) is an integral membrane protein that transports
nucleosides and analog drugs across cellular membranes. Very little is known about intracellular processing
and localization of hENT1. Here we show that disruption of a highly conserved triplet (PWN) near the N-
terminus, or the last eight C-terminal residues (two hydrophobic triplets separated by a positive arginine)
result in loss of plasma membrane localization and/or transport function. To understand the role of speciﬁc
residues within these regions, we studied the localization patterns of N- or C-terminal deletion and/or
substitution mutants of GFP-hENT1 using confocal microscopy. Quantiﬁcation of GFP-hENT1 (mutant and
wildtype) protein at the plasma membrane was conducted using nitrobenzylthioinosine (NBTI) binding.
Functionality of the GFP-hENT1 mutants was determined by heterologous expression in Xenopus laevis
oocytes followed by measurement of uridine uptake. Mutation of the proline within the PWN motif disrupts
plasma membrane localization. C-terminal mutations (primarily within the hydrophobic triplets) lead to
hENT1 retention within the cell (e.g. in the ER). Some mutants still localize to the plasma membrane but
show reduced transport activity. These data suggest that these two regions contribute to the structural
integrity and thus correct processing and function of hENT1.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
Nucleoside transporters (NTs) play an essential role in the
transport of nucleosides and nucleoside analog drugs, such as
gemcitabine and ﬁaluridine, across cellular membranes [1–3]. NTs
have been classiﬁed into two families known as concentrative (C) NTs
and equilibrative (E) NTs. CNTs use ion (i.e. Na+) gradients to co-
transport nucleosides across the membrane, while ENTs transport
nucleosides in a passive manner down an endogenous concentration
gradient [4,5]. ENTs are ubiquitously expressed, in contrast to the
CNTs, which have a more limited tissue distribution [6,7].
ENTs belong to the SLC29 transmembrane protein family of
nucleoside transporters [4]. The predicted topology of ENTs suggests
that these proteins have a unique 11 transmembrane structure with
an intracellular N-terminus and an extracellular C-terminus [8,9]. To
date, four isoforms of these proteins have been identiﬁed, ENT1–ENT4ide transporter 1; GFP, Green
tein disulﬁde isomerase; NBTI,
5; fax: +1 416 736 5698.
ll rights reserved.[4,10]. Among the best characterized ENTs are the human ENTs, or
hENTs, particularly hENT1 [4]. The hENT1 protein is primarily
localized to the plasma membrane although [1] have proposed that
hENT1 is also targeted to the mitochondria [1,11] following ER export.
However, the regulatory signals and mechanisms underlying intra-
cellular processing, targeting/trafﬁcking or function for all ENTs are
poorly understood.
In order for membrane proteins, such as hENT1, to localize to the
plasma membrane, they must undergo correct processing, targeting
and trafﬁcking. These processes are aided by many different
interacting partners that regulate folding, ER export and/or incorpo-
ration into vesicles [12]. Correct folding ofmembrane proteins is aided
by chaperone proteins such as binding protein (BiP), which associates
with hydrophobic residues and, in an ATP dependent manner,
“guides” the alignment of peptides that will later be linked by
disulﬁde bridges formed by protein disulﬁde isomerase (PDI) [12–16].
Besides folding, interacting proteins also play a role in allowing a
protein to travel along the secretory pathway to its ﬁnal destination.
These interacting partners (i.e. coatomer proteins or clathrin) allow a
protein to be incorporated into vesicles for transport and later
incorporation into their target membranes. For all these packaging/
translocation steps, speciﬁc motifs within the protein sequence are
Table 1
Primers used in the construction of the truncation and substitution mutants of GFP-
hENT1 The C-terminal amino acid sequences of wildtype GFP-hENT1 and the various
mutants are shown along with the primers (in 5′ to 3′ direction) used to generate them.
Primer Primer sequence Mutant
hENT1
Fwd
CGG GGT ACC CCG ATG CGG CTA AAC ATG ACA ACC AGT
CAC CAG CCT CAG
N/A
hENT1-T2
reverse
TCC CCG CGG GGA TCA TGC CTC GAA CAG GAA GGA GAA
AAC AGC CCC CAG TGC
SFLFRA - -
hENT1-T4
reverse
TCC CCG CGG GGA TCA GAA TCA GAA CAG GAA GGA GAA
AAC AGC CCC CAG TGC CAG ACC
SFLF - - - -
hENT1-T6
reverse
TCC CCG CGG GGA TCA GAA GGA GAA AAC AGC CCC CAG
TGC CAG ACC CAG ACA
SF - - - - - -
hENT1-A
reverse
CCG CGG GGA TCA CAC AAT TGC CCG TTT CAG GAA GGA
GAA AAC AGC CCC
SFLKRAIV
hENT1-C
reverse
CCG CGG GGA TCA CAC AAT TGC CCG TTT CTT TTT GGA
GAA AAC AGC CCC
SKKKRAIV
hENT1-D
reverse
TCC CCG CGG GGA TCA CAC AAT TGC CCG GAA CAG TTT
GGA GAA AAC AGC CCC
SKLFRAIV
hENT1-E
reverse
TCC CCG CGG GGA TCA TGC CTC GAA CAG GAA GGA GAA
AAC AGC CCC CAG TGC
SFLFEAIV
hENT1-G
reverse
TCC CCG CGG GGA TCA CAC AAT TGC CCG TGC AGC TGC
GGA GAA AAC AGC CCC
SAAARAIV
hENT1-H
reverse
TCC CCG CGG GGA TCA CAC AAT TGC CCG GAA CAG GGC
GGA GAA AAC AGC CCC
SALFRAIV
hENT1-I
reverse
TCC CCG CGG GGA TCA CAC AAT TGC CCG GGC CAG GAA
GGA GAA AAC AGC CCC
SFLARAIV
hENT1-J
reverse
TCC CCG CGG GGA TCA CAC AAT TGC GAG GAA CAG GAA
GGA GAA AAC AGC CCC
SFLFLAIV
hENT1-K
reverse
TCC CCG CGG GGA TCA CAC AAT TGC GTG GAA CAG GAA
GGA GAA AAC AGC CCC
SFLFHAIV
hENT1-L
reverse
TCC CCG CGG GGA TCA CAC TTT TGC CCG GAA CAG GAA
GGA GAA AAC AGC CCC
SFLFRAKV
The speciﬁc truncation or residue substitutions are indicated in bold.
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structural conformation, is therefore crucial for precise protein
folding, ER export and trafﬁcking and single point mutations in a
protein sequence can signiﬁcantly affect any one of these steps [18].
In recent years, many studies have shown that the N- and/ or C-
termini have a regulatory role for a large number of membrane
proteins. For instance, the human kidney anion exchanger (kAE1)
possesses two tyrosines (one located at the N-terminus and one
located at the C-terminus) which play a role in correct basolateral
trafﬁcking of kAE1. Disruptions to these two residues result in
retention of the protein within the trans-Golgi network [19].
Similarly, alanine substitutions in the C-terminus of the multidrug
resistance P-glycoprotein ABC-type transporter (P-gp), result in
misfolding and arrested cell surface expression [20] and a number
of other studies on the processing of transporters (e.g. DAT, hSVCT1,
GAT1) have demonstrated that motifs involved in ER export and/or
plasma membrane targeting are located in the C-terminus [21–24].
Disruption of thesemotifs results in retentionwithin the ER, likely due
to ER quality control mechanisms [25]. In addition, studies (e.g. on the
Cystic ﬁbrosis transmembrane conductance regulator) show that the
C-terminus contributes to protein function through interaction with
other proteins [26]. These data suggest that the C-terminus of a
transporter (which is typically intracellular in these studies) is a
common location for regulatory motifs. However, the predicted
structure of hENT1 possesses an extracellular C-terminus calling
into question the role of this region of the protein for this transporter.
Indeed, virtually nothing is known about folding, ER processing or
trafﬁcking of hENT1. A small number of individual residues in ENT1
(or orthologs) have been implicated in targeting and function in other
studies [i.e. 27–29]. However, the existence of regulatory motifs and
the underlying mechanisms involved in regulation of hENT1 proces-
sing and localization are still largely unknown.
To better understand processing and localization of hENT1, we
studied the contribution of the C-terminus, a region implicated in
targeting in other transporters [e.g. 30]. We also looked at the
contribution of the very highly conserved PWN motif at the N-
terminus. This motif is present in almost every member of the ENT
family identiﬁed to date and is therefore likely to have a critical role in
hENT1 biology [10].
2. Materials and methods
2.1. Generation of the GFP-hENT1 mutants
Mutations to the PWN triplet were introduced using the
Stratagene Quikchange mutagenesis kit (Statagene, CA, USA) onto a
GFP-hENT1 template following the manufacturer's instructions.
Primers for the C-terminal mutants were synthesized which
introduced a KpnI restriction site before the GFP-hENT1 start codon,
and a stop codon followed by SacII site after the last eight amino acids
of the hENT1 C-terminus. (Table 1 lists all primers). A unique NotI
restriction site was introduced between the KpnI site and the start
codon for identiﬁcation of positive clones after ligation. None of the
introduced restriction sites altered the protein sequence. All the
mutants were then ampliﬁed by means of Polymerase Chain Reaction
(PCR) using GFP-hENT1 as a template.
A KpnI/SacII vector fragment from pEGFP-C1 (Clontech Laborato-
ries Inc., Mississauga, ON, Canada) and a KpnI/SacII GFP-hENT1 insert
fragment were isolated using the Gel Extraction Kit (Qiagen Inc.,
Canada) and ligated using T4 DNA ligase (New England BioLabs;
Pickering, ON, Canada). Ligation reactions were incubated overnight
at 16 °C and then transformed into Novablue competent cells (EMD
Biosciences, Mississauga ON, Canada). Aliquots were plated on LB-
agar supplemented with 50 μg/mL kanamycin. Single colonies from
these plates were grown in LB medium supplemented with
kanamycin. Plasmid DNA was isolated from bacterial cultures usingthe Genelute HP Plasmid Mini Prep Kit (Sigma-Aldrich, Oakville ON,
Canada) and analyzed on a 1% (w/v) agarose gel following either a
NotI digestion or a double digestion of SacII and NotI (New England
BioLabs; Pickering, ON, Canada).
Positive clones for the PWN and C-terminal mutants were
sequenced in both forward and reverse directions at the York
University Core Molecular Sequencing Facility. Samples showing the
correct sequence, including the desired mutation (if applicable) were
puriﬁed using the Endo-Free Maxi prep Kit (Qiagen Inc., Canada).
2.2. Cell culture
COS-7 and MCF-7 cells were maintained in Dulbecco's Modiﬁed
Eagle's Medium (DMEM; Gibco BRL, MD, USA) supplemented with
10% (v/v) fetal bovine serum (FBS; Gibco BRL, MD, USA). Cells were
grown on 10 cm2 plates at 37 °C in a humidiﬁed incubator and a 5%
CO2 atmosphere.
2.3. Cell transfection for confocal analysis
COS-7 and MCF-7 cells were seeded in 6-well plates on glass
coverslips and allowed to grow at 37 °C in 2 mL DMEMwith 10% (v/v)
FBS for 24h to a density of approximately 80%. One hour prior to
transfection, the medium was replaced with 1 mL fresh DMEM with
10% (v/v) FBS. For the transfections, 2 μg of plasmid DNA was mixed
with 250 μl DMEM (without FBS). In a separate vial, 12 μl of
LipofectAMINE 2000 (Invitrogen, Carlsbad, CA, USA) was added to
100 μl FBS free DMEM. The two solutions were incubated separately
for 5min then mixed together and incubated at room temperature for
20min. The mixture was then added drop wise to cells. The 6-well
plateswere incubated overnight in a humidiﬁed incubator at 37 °C and
5% CO2 atmosphere. The transfected cells were ﬁxed with 2% (w/v)
paraformaldehyde (PFA) 20h post transfection and subjected to
organelle labeling.
Table 2
Localization of the hENT1 PWN mutants (residues 28–30).
Mutant Mutant
Sequence
Localization
PM I
Wt hENT1 PWN +++ +
PWA PWA +++ +
PAN PAN +++ +
PAA PAA +++ +
AWN AWN − +++
AWA AWA − +++
AAN AAN − +++
AAA AAA − +++
pEGFP-C1 – − +++ (diffuse)
Substitutions are indicated in bold and are underlined.
PM plasma membrane.
I Intracellular.
+++ ≥60 of cells showing hENT1 localization in indicated area.
++ 40–59% of cells showing hENT1 localization in indicated area.
+ 6–39% of cells showing hENT1 localization in indicated area.
− ≤5% of cells showing hENT1 localization.
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COS-7 or MCF-7 cells were seeded in 10 cm2 plates and allowed to
grow overnight at 37 °C in 10 mL DMEMwith 10% (v/v) FBS to a density
of approximately 80%. One hour prior to transfections, the medium in
all plates was replaced with 4 mL fresh DMEM with 10% (v/v) FBS.
For transfections, 15 μg of plasmid DNA was mixed with 1.5 mL DMEM
(without FBS). In a separate vial, 80 μl of LipofectAMINE 2000
(Invitrogen, Carlsbad, CA, USA) was added to 1.5 mL DMEM without
FBS. The two solutions were incubated as described above and the ﬁnal
mixturewas slowlypouredonto cells. Plateswere incubatedasdescribed
above. Cells were collected 18h post transfection. Equivalency of trans-
fection across the experiments was determined by comparing the total
percentage of ﬂuorescing cells between transfected samples within a
single experiment. Experiments with less than 65% transfection efﬁ-
ciency were not used. GFP-hENT1 wildtype, which shows characteristic
plasmamembrane staining, was used as a positive control while pEGFP-
C1emptyvector,which showsdiffuse cytoplasmic staining,wasusedas a
negative control (see Fig. 1A and B respectively) in all experiments.
2.5. Labeling of organelles and immunocytochemistry
Transfected cells were treated with the intracellular dyes Lyso-
Tracker Red DND-99 or MitoTracker Red CMXRos (Molecular Probes
Inc. Eugene, OR) for 30min to label the lysosomes or mitochondria
respectively. Labeled cells were then mounted cell side down on glass
microscope slides using one drop of mounting medium (DAKOcyto-
mation, Mississauga, ON, Canada).
Immunocytochemistry was performed using the SelectFX™ Alexa
Fluor® 488 Endoplasmic Reticulum Labeling Kit (Molecular Probes,Fig. 1. Confocal microscopy of mammalian cells transfected with PWN GFP-hENT1
mutants. A. pEGFP-hENT1 wildtype; B. GFP-empty vector negative control; C. hENT1-
PAN; D. hENT1-PWA; E. hENT1-PAA; F. hENT1-AAN; G. hENT1-AWN; H. hENT1-AAA.
Presence of the proline residue results in increased GFP-hENT1 at the plasma
membrane compared to mutants lacking the proline. Bar=10 μm.Invitrogen, Carlsbad, CA, USA) forﬁxed cells. The sampleswere treated
according to the manufacturer's protocol except that instead of using
the AlexaFluor® 488 goat anti-mouse IgG as a secondary antibody,
AlexaFluor® 594 goat anti-mouse IgG was used since the 488 variant
shows a green signal which would be indistinguishable from the GFP
signal. Coverslips were mounted cell side down as described above.
All slides were viewed at the York University Microscopy and
Imaging Facility using the Olympus Fluoview 300 confocal microscope
(60× oil immersion lens, 1.4 N.A.) and Olympus Fluoview 300 imaging
software (version 4.3). A minimum of 10 ﬁelds of view were analyzed
to determine localization patterns for pEGFP-C1 empty vector, hENT1
wildtype and each mutant.
All the confocal images show a single, representative, section of a
Z-series taken through the entire cell. The section was chosen to show
plasma membrane localization or ER localization.
ToquantifyhENT1presenceat theplasmamembraneon confocal, the
percentage of cells showing plasma membrane localization was deter-
mined and compared to thenumberof cells showing intracellular hENT1,
for an average of 10 ﬁelds of view. Observations were done without
knowledge of themutant being viewed. Cells showing deﬁnitive plasma
membrane staining withminimal internal localization were classiﬁed as
the protein being present at the plasma membrane. Cells lacking deﬁni-
tive membrane staining were classiﬁed as the protein being retained.
A complete list of all the mutants and their localizations is shown
in Tables 2–5.Table 3
Localization and function of the PWN mutants.
Sample % cells showing plasma
membrane ﬂuorescence
% NBTI binding
versus GFP-hENT1
% function versus
GFP-hENT1
PWN 71±2.2 100±0 100±0
pEGFP-C1 0±0 6±0.6 0±0
PWA 55±3.1 76±17.6 37.2±16.1
PAN 59±1.5 74±13.1 29.8±13.3
PAA 31±3.5 49±10.1 26.8±18.5
AWN 6±1.2 NT 3.5±1.5
AWA 1±0.3 NT NT
AAN 2±0 25±5.5 NT
AAA 0±0 NT NT
The percentage of cells where ﬂuorescence was observed at the plasma membrane is
based on analysis of 10 ﬁelds of view in at least three independent experiments (n≥3).
Data are presented as an average±S.E. NBTI binding of each sample is represented as
pooled data±S.E, from at least two independent experiments (n≥2), each binding
assay conducted in duplicate. Values are presented as an average compared to NBTI
binding observed with wildtype GFP-hENT1, which is set at 100%. Function (transport
activity) is presented as pooled data±S.E, from at least three independent experiments
(n≥3), with approximately 15 oocytes used per assay. Values are presented as an
average compared to wildtype GFP-hENT1, which is set at 100% activity.
NT not tested.
Table 4
Localization of the hENT1 C-terminal mutants.
Mutant Mutant sequence Mutation type Localization
PM I
wt hENT1 SFLFRAIV – +++ +
hENT1-T2 SFLFRA - - Truncation + +++
hENT1-T4 SFLF - - - - Truncation + +++
hENT1-T6 SF - - - - - - Truncation − +++
hENT1-T8 - - - - - - - - Truncation − +++
hENT1-A SFLKRAIV Non-polar→ positive + +++
hENT1-C SKKKRAIV Non-polar→ positive − +++
hENT1-D SKLFRAIV Non-polar→ positive + +++
hENT1-E SFLFEAIV Positive→ negative ++ ++
hENT1-G SAAARAIV Non-polar→ non-polar ++ ++
hENT1-H SALFRAIV Non-polar→ non-polar +++ +
hENT1-I SFLARAIV Non-polar→ non-polar +++ +
hENT1-J SFLFLAIV Positive→ non-polar +++ +
hENT1-K SFLFHAIV Positive long chain→ positive bulky chain +++ +
hENT1-L SFLFRAKV Non-polar→ positive + +++
hENT1-long SFLFRAIVGAARDPPDLDN Extension − +++
pEGFP-C1 – – − +++ (diffuse)
Truncation or residue substitutions are indicated in bold and are underlined.
PM plasma membrane.
I intracellular.
+++ ≥60 of cells showing hENT1 localization in indicated area.
++ 40–59% of cells showing hENT1 localization in indicated area.
+ 6–39% of cells showing hENT1 localization in indicated area.
− ≤5% of cells showing hENT1 localization in indicated area.
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Nitrobenzylthioinosine (NBTI) is a tight binding, high afﬁnity
(nM), speciﬁc inhibitor of hENT1 [8]. Measurement of levels of free
versus bound NBTI in whole cells is frequently used as an indication of
the amount of ENT1 present at the plasma membrane [31]. Confocal
data were therefore complemented by NBTI binding assays which
provide an additional quantitative analysis of hENT1 protein at the
membrane. NBTI binding assays were done using standard procedures
[32] at room temperature in a 1 mL ﬁnal volume of NBTI binding
buffer (10 mM Tris–HCl, 100 mM KCl, 0.1 mM MgCl2•6H2O, 0.1 mM
CaCl2•2H2O at a ﬁnal pH of 7.4). Samples were incubated in theTable 5
Determination of C-terminal mutant localization and function.
Sample Sequence % cells showing
plasma
membrane
ﬂuorescence
% NBTI binding
versus
GFP-hENT1
% function
versus
GFP-hENT1
hENT1 wildtype SFLFRAIV 71±2.2 100±0 100±0
pEGFP-C1 – 0±0 6.0±0.7 0±0
hENT1-T2 SFLFRA - - 27±1.5 14±8.5 0±0
hENT1-T4 SFLF - - - - 16±2.0 19±1 0±0
hENT1-T6 SF - - - - - - 0±0 NT NT
hENT1-T8 - - - - - - - - 0±0 8±1.5 2.8±1.0
hENT1-A SFLKRAIV 13±3.3 NT 2.5±2.5
hENT1-C SKKKRAIV 0±0 3±2.5 NT
hENT1-D SKLFRAIV 41±10.5 48±2.6 0.5±0.5
hENT1-E SFLFEAIV 51±10.0 56±11.0 45.8±11.5
hENT1-G SAAARAIV NT 51±9.0 31.6±14.5
hENT1-H SALFRAIV 64±3.5 87±13.5 54.6±13.8
hENT1-I SFLARAIV 68±1 70±13.3 43.25±4.8
hENT1-J SFLFLAIV NT 83±16 40.9±10.5
hENT1-K SFLFHAIV 69±0.5 81±19.0 58.8±5.71
hENT1-L SFLFRAKV NT 29±7.5 36.17±10.9
The percentage of cells where ﬂuorescence was observed at the plasma membrane is
based on an average of 10 ﬁelds of view in at least three separate trials. Data are
presented as an average±S.E. NBTI binding is tested in duplicate within each assay and
values are represented as an average percentage versus wildtype hENT1, with wildtype
hENT1 considered to be 100%. NBTI binding of each sample is represented as pooled
data from n≥2±S.E. Function is presented as pooled data±S.E. from 15 oocytes per
sample per trial, with at least three trials for control or mutant.
NT not tested.presence or absence of 10 μM NBTI with [3H] NBTI ranging in
concentration from 0.2nM to 7.5nM (Moravek, CA, USA) [32]. For
each analysis, pEGFP-C1 was used as a negative control (with NBTI
binding levels reﬂecting endogenous levels of ENT1 in both COS-7 and
MCF-7 cells) and pEGFP-hENT1 was used as a positive control (with
NBTI binding levels reﬂecting the degree of over-expression of GFP-
hENT1 in both COS-7 and MCF-7 cells). All samples were incubated
for 50min after addition of 100 μl transfected cell suspension
(~1.5×105 cells). Reactions were stopped with 5 mL of ice cold
binding buffer. The solutions were then ﬁltered through Whatman
GF/B ﬁlters (Fisher Scientiﬁc, Ottawa, Canada) and washed with an
additional 8 mL of binding buffer. Radioactivity levels were measured
using a scintillation counter (1600 TR Scintillation Analyzer, Packard)
and then subjected to non-linear regression analysis (GraphPad,
PRISM version 4).
2.7. cRNA synthesis
To allow for in vitro transcription, a T7 promoter sequence was
introduced before the start codon of each mutant as indicated in the
mMessage mMachine kit (Ambion, Texas, USA) instruction manual.
PCR products were sequenced as previously described. RNA tran-
scripts were subsequently generated according to the mMessage
mMachine kit manufacturer instructions. The concentration and size
of the RNA transcripts was determined using a spectrophotometer
and agarose gel electrophoresis.
2.8. Oocyte extraction and injection
To test functionality Xenopus laevis oocytes were used for
heterologous expression since they lack endogenous nucleoside
transport activity [31]. Oocytes were removed from adult female
frogs as described previously [34]. After extraction, stages V–VI
oocytes were stored overnight at 18–20°C in ND96 medium pH7.6
[96 mM NaCl, 2 mM KCl and 5 mM Hepes supplemented with
gentamicin sulphate (50µg/ml), penicillin G (100µg/ml), 2 mM
pyruvic acid, 90 mg theophylline, 1 mM MgCl2 and 1.8 mM CaCl2].
Follicle layers were removed by treating the oocytes with collagenase
Type I (1 mg/ml) (Sigma-Aldrich, Oakville ON, Canada) for 20–40min
in calcium-free saline.
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(positive control) or water (negative control) was individually
injected into ~15 oocytes per treatment (mutant, positive control or
water) per trial using a nanoinjector (Drummond Scientiﬁc Company,
PA, USA). Following injection, oocytes were kept at room temperature
for 72h in ND96++++ medium. To assess transport activity, oocytes
were ﬁrst incubated for 15min in choline chloride transport buffer
(100 mM ChCl, 2 mM KCl, 1 mM CaCl2, 1 mM MgCl2, and 10 mM
Hepes, at pH7.5). The transport buffer was then removed and oocytes
were incubated for 60min in 200 µl fresh choline chloride transport
buffer containing 100 µM uridine and 0.1 mCi/ml [3H] uridine.
Following incubation, extracellular uridine was removed by six
rapid 1 mL washes (all carried out within one minute) using NBTI
containing choline chloride transport buffer (NBTI prevents nucleo-
side efﬂux during the washes). Each single oocyte was then placed
into a separate scintillation vial containing 200 µl of 1% (w/v) SDS.
Vials were subjected to vigorous shaking for 45min to dissolve the
oocyte. Finally, 2 ml of scintillation ﬂuid was added to each vial
followed by liquid scintillation counting using the 1600 TR Scintilla-
tion Analyzer (Packard).
3. Results
3.1. Analysis of location of wildtype hENT1 conﬁrms predicted
localization patterns
The use of recombinant tagged-hENT1 is well established as a
method for the study of hENT1 [e.g. 35] and many studies show
that hENT1 is typically localized to the plasma membrane [29,31].
GFP-tagged hENT1 was used to study localization patterns since no
reliable commercial antibody against endogenous hENT1 exists for
confocal microscopy. Transfection of GFP-hENT1 into both MCF-7 and
COS-7 cells showed predominantly membrane localization patterns as
expected (Figs. 1A and 2A), suggesting that no difference in expression/
localization exists between these two cell types.Wedid not observe any
GFP-hENT1 co-localization with the mitochondria (as has been sug-
gested in previous studies) [1]. Localization patterns of all substitution
and deletion mutants were compared to GFP-hENT1 wildtype. Based
on confocal analyses, approximately 70% of wildtype GFP-hENT1 was
present at the plasma membrane. The remaining GFP-hENT1 is found
intracellularly where it is most likely undergoing processing within the
secretory pathway. pEGFP-C1, the GFP-empty vector, was used as a
negative control and showed no plasma membrane localization but
rather, a diffuse cytoplasmic staining (Figs. 1B and 2B).
3.2. Presence of P28 within the N-terminal PWN triplet is required for
plasma membrane localization
The PWN motif is found in almost every ENT family member
identiﬁed to date (Fig. 3A) [10].We therefore determinedwhether the
residues whichmake up the PWN sequence play a role in the ability of
hENT1 to reach the plasma membrane by substituting one or more
residues within this triplet with alanines. Our data showed that
preservation of P28 within the PWN triplet led to the presence of
more GFP-hENT1 at the plasma membrane compared to mutants
lacking P28 (Fig. 1, Tables 2 and 3). Replacing either W29 or N30 with
an alanine (while preserving P28) reduced localization at the plasma
membrane by approximately half based on confocal microscopy;
Table 3. However, replacing both W29 and N30 with alanines
(without mutating P28) resulted in about one third of the control
level of GFP-hENT1 expression at the plasma membrane suggesting
that the presence of either residue, in combination with P28, is
necessary for effective plasma membrane localization (Table 3). GFP-
hENT1 mutants, where P28 was substituted with an alanine, show
very low levels of plasma membrane localization regardless of the
presence of other components of the triplet.Since ER quality control mechanisms can cause retention of
proteins [15] we determined if the mutants were localized to the ER
by determining if they were co-localizing with a well established ER
marker, protein disulﬁde isomerase (PDI). Some ER co-localization of
the PWN mutants was observed suggesting that mutations in the
PWN motif led to possible misfolding or ER export motif disruption.
However, intracellular localization was not exclusive to the ER but
also to other unidentiﬁed structures.
3.3. Truncation of two, four, six or eight C-terminal amino acids result in
loss of plasma membrane localization
We had initially found that elongating the C-terminus by 11 amino
acids resulted in almost complete abolition of cell surface expression
suggesting that the integrity of the C-terminus was important in
plasma membrane localization. Therefore, to explore the possible
role of the C-terminus in directing or regulating localization of hENT1
to the plasma membrane, we made various truncation mutants
(Table 4). We observed that removal of the last two amino acids (ΔIV,
mutant T2) or last four amino acids (mutant T4, ΔRAIV) resulted in
the majority (~75% or more) of GFP-hENT1 proteins being retained
within the cell, (Table 5). Removal of the last six (mutant T6,ΔLFRAIV)
or eight amino acids (mutant T8, ΔSFLFRAIV) resulted in no plasma
membrane localization. We hypothesized that mutant hENT1 was
being retained within the ER and conﬁrmed ER co-localization using
the PDI antibody described above. Our results show that wildtype
GFP-hENT1 is primarily localized at the plasma membrane (Fig. 2A),
while the T6 and T8 mutants both show retention of the mutant
within the cell including co-localization with the ER (e.g. mutant T6,
Fig. 2C). Mutants T2 and T4 show both plasma membrane and ER co-
localization (i.e. mutant T2 Fig. 2D and E). Taken together, these data
suggest that the last 8 amino acids may be critical for folding/ER
export and plasma membrane localization. Therefore, we next
determined which speciﬁc residues were responsible for these effects.
3.4. Identiﬁcation of speciﬁc C-terminal residues involved in correct
localization of hENT1
While truncation mutations suggest that an intact hENT1 C-
terminal region is required for localization to the plasmamembrane, it
is not clear whether speciﬁc residues or motifs within this region are
required. Therefore, substitutions were introduced into the SFLFRAIV
region of the hENT1 C-terminus and localization patterns were
analyzed by confocal microscopy (Table 4, mutants A–L). Amino acid
substitutions preserve the length of the protein and thus effects are
due to changes in residue rather than a truncated protein as has been
demonstrated in similar studies with other transporters [e.g. 23,24].
Since the highly hydrophobic triplet, FLF, is conserved in both
hENT1 and hENT2, which both localize to the plasma membrane
[6,36] as well as a many (but not all) other ENTs (Fig. 3B), we
hypothesized that this might be an important sequence for allowing
hENT1 to reach the plasma membrane. We determined the effect of
charge reversal within this triplet by introducing positively charged
lysines (K, mutants A–D; Tables 4 and 5). In addition, non-polar
alanines were substituted to study the effect of changing the speciﬁc
residues in the FLF motif but conserving the charge (mutants G–I). A
charge substitution mutant was also made by introducing a lysine
in the second hydrophobic triplet present in the C-terminal, AIV
(mutant L; Table 4).
Substitution of a single positive charge in the FLF triplet,
substantially reduces the overall presence of hENT1 at the plasma
membrane (mutants A and D; Table 5) while mutation of all three
residues of the FLF amino acid sequence (mutants C; Table 5) results
in a complete loss of hENT1 expression at the plasma membrane with
concomitant ER co-localization visible suggesting retention of the
mutated hENT1 in the ER (Fig. 2F, mutant C, FLF to KKK).
Fig. 2. Confocal analysis of GFP-hENT1 C-terminal truncation and substitution mutants in COS-7 cells. A. GFP-hENT1 wildtype. B. pEGFP-C1 empty vector. C. GFP-hENT1-T6
colocalizes with the ER. D. GFP-hENT1-T2 is present at the plasmamembrane. E. GFP-hENT1-T2 colocalizes with the ER (yellow inmerged image). F. GFP-hENT1-Cmutant colocalizes
with the ER and unidentiﬁed intracellular structures. G. GFP-hENT1-E is present at the plasma membrane. H. GFP-hENT1-E colocalizes with the ER. PDI=protein disulﬁde isomerase
ER marker. Bar=10 μm.
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Fig. 3. ClustalW alignment of ENT orthologs showing the highly conserved regions of
study. A. Selection of ENTs from diverse taxons showing conservation of the PWNmotif
(boxed). B. Selection of ENTs from diverse taxons showing C-terminus where the
hydrophobic triplet–charged residue–hydrophobic triplet pattern is present at least in
part. Asterisks represent identical residues, colons represent similar residues.
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triplet, which do not reverse the charge but rather conserve the
hydrophobicity, have very little effect on the localization of the protein
since it is found predominantly at the plasma membrane (mutants H
andmutant I; Table 5).However,when all three residues are replaced by
alanines, the mutant hENT1 is predominantly retained (mutant G;
Table 5) compared to wildtype hENT1. Introduction of a lysine into the
secondhydrophobic triplet in theC-terminus (AIV), leads toa signiﬁcant
retention of hENT1 (mutant L; Table 5). This suggests that conservation
of the hydrophobic character of the residue at this site is important for
hENT1 localization.
To investigate the role of the positively charged arginine (R) in
localization, a negatively charged glutamic acid (E) or a non-polar
leucine (L) was substituted (Table 4). In addition, since arginine
possesses a long side chain, we also determined whether substitution
with another positive amino acid containing a bulky side chain,
histidine (H), would affect plasma membrane localization.
Results show that the effect of the substitution is dependent on
the charge of the substituted residue. Thus, introduction of a negative
glutamic acid (E) results in less protein at the plasma membrane
combined with evidence of ER co-localization, (Fig. 2G and H).
However, introduction of a non-polar leucine (L) or a bulky positive
histidine (H) has no effect on plasma membrane localization
(Table 5). These data suggest that either a positive or non-polar
residue at the−4 position of the C-terminus is required for hENT1 to
be present at the plasma membrane and that a negatively charged
residue in this position disrupts processing and therefore plasma
membrane localization.3.5. Determination of hENT1 presence at the plasma membrane by NBTI
binding conﬁrms confocal results
To conﬁrm our plasma membrane localization data derived from
confocal analyses, we conducted binding assays for selected mutants.Results demonstrate that transfection of wildtype GFP-hENT1 into
COS-7 cells shows the highest level of NBTI binding (deﬁned as 100%)
demonstrating high levels of plasmamembrane expression compared
to the negative control which showed 10% NBTI binding relative to the
overexpressed GFP-hENT1 which is consistent with NBTI binding by
endogenous ENT1 in these cells (Table 5).
The requirement for the presence of P28 within the PWN triplet in
effective plasma membrane localization was conﬁrmed in that
substitution of either the tryptophan (W) or the asparagine (N) in
the triplet did not signiﬁcantly affect binding levels compared to
control (Table 3). However, mutation of both W29 and N30
simultaneously strongly reduced binding suggesting that W29 and/
or N30 need to be present along with P28 for effective plasma
membrane localization (Table 3).
Alterations to the C-terminus that result in truncation lead to NBTI
binding which is only slightly higher (e.g. T2 and T4) or equivalent to
background (e.g. T8 Table 5) suggesting that important residues or
motifs for hENT1 localization to the plasma membrane lie within this
region and supporting the conclusions derived from the confocal data
(Table 5). The hydrophobicity of the FLFmotif appears to be important
since non-polar to positive substitutions (mutants A–D) result in a
considerable reduction in NBTI binding levels versus non-polar to
non-polar mutations (mutants G–I; Table 5). Substitution of the
positive arginine (R) with a negative glutamic acid (mutant E) led to
approximately half the level of control binding conﬁrming the
conclusions from the confocal data which suggested that the change
in charge signiﬁcantly affected localization to the plasma membrane
(Table 5).
3.6. Functionality of hENT1 truncation and substitution mutants
Confocal microscopy and NBTI binding provide information on the
location of GFP-hENT1 and the mutants. However neither assay
addresses the effect of these mutations on the functionality of proteins
at the plasma membrane. Therefore, to determine if mutants which
reach the plasma membrane, at least in part (Tables 2 and 4), were
indeed functionally equivalent to wildtype GFP-hENT1, we measured
uptake of uridine, a well-established universal permeant, in Xenopus
laevis oocytes. Functionality of themutants is expressed as a percentage
of the uptake seen by wildtype GFP-hENT1 (deﬁned as 100%) and is
compared to uptake by the negative controls, pCDNA3.1+empty vector
or water injected oocytes, (which both showed similar results; deﬁned
as 0%).
Confocal and NBTI binding data suggest that the presence of the
proline (in the PWN motif) ensures that at least half of the protein
gets to the membrane. However, the transport data suggest that these
proteins, although correctly localized are functionally compromised
since uptake is decreased (Table 3). This decrease is more than would
be anticipated on the basis of only half the protein reaching the
membrane. The presence of the proline residue appears to contribute
to the structural integrity of the protein, which enhances its
processing and targeting to the plasmamembrane while the presence
of the other two residues (WN) appear to provide more subtle
contributions to function.
Deletion mutants of the hENT1 C-terminus, which are partially or
completely retained based on confocal and NBTI binding analyses,
show reduced or non-existent uptake (e.g. T4 and T8<5%, Table 5).
Similar to our observations with confocal microscopy and NBTI
binding, we noted that transport activity of C-terminal substitution
mutants depends on the residue or region being substituted. Lysine
substitutions, within the hydrophobic triplets (i.e. mutants A, D and
L), show decreased transport activity, which correlates with reduced
presence at the plasma membrane. Of these lysine substitution
mutants, the most striking is mutant D (SKLFRAIV), which shows
approximately 41% of GFP-hENT1 at the plasma membrane based on
confocal microscopy and 48% based on NBTI binding, but virtually no
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phenylalanine in the FLF triplet is particularly important for function.
This residue is conserved in many but certainly not all ENTs (Fig. 3B)
and we noted that a conservative mutation of the phenylalanines to
an alanine (mutants H and I; Table 5; which is present at the plasma
membrane in levels equivalent to wildtype hENT1) is less disruptive
to transport activity (i.e. ≤50%) suggesting that a non-polar residue
(rather than speciﬁcally a phenylalanine) is important for function in
this region. Taken together with the confocal and binding data, our
functionality data suggest a role for charge in both function and
localization.
Analysis of the contribution of the positively charged arginine in
the C-terminal region of hENT1 reveals that while a positive or non-
polar amino acid (mutants K and J respectively) is sufﬁcient to allow
for plasma membrane localization, introduction of these residues
results in an overall reduction in transport activity (Table 5).
However, conservation of the positive charge (mutant K; R H)
retains transport activity which is closer to wildtype versus other
mutations at this residue. Lastly, a positive to negative substitution in
this region (mutant E) shows a decreased transport activity (~45% of
wt) which correlates with a decreased presence at the plasma
membrane (50%).
4. Discussion
For effective nucleoside and nucleoside analog drug transport to
occur, hENT1 must be both localized and fully functional at the
plasma membrane [11]. However, hENT1, like other membrane
proteins, must ﬁrst be folded correctly and be checked by ER quality
control mechanisms so that it can be exported from the ER and
continue to pass through the secretory pathway before reaching the
plasma membrane [13,25]. Changes in the sequence of critical
regions of the protein that are responsible for any of these processes
can cause disruptions in one or more of the processing steps
resulting in ER retention, misrouting or loss of function [37–39].
Based on current models of hENT1 topology, it is likely that hENT1 is
inserted into the ER membrane during translation in an orientation
that leaves the N-terminal PWN triplet in the membrane facing the
ER lumen and C-terminus extending into the ER lumen. Thus, while
many other plasma membrane transporters possess targeting/
trafﬁcking motifs in the C-terminus, the predicted orientation of
hENT1 during processing would seem to preclude a role for the PWN
triplet or the C-terminus in an interaction with cytoplasmic proteins
involved in targeting and trafﬁcking of the protein within the cell.
Targeting and trafﬁcking motifs thus have yet to be fully identiﬁed.
Moreover, caution is required when interpreting data which
correlate localization patterns to speciﬁc mutations (motifs) since
regions involved in the structural integrity of the protein, and thus
function, must be retained for correct intracellular processing and
targeting to the plasma membrane. Function, therefore, relies on
correct processingwhich is correlatedwith the structural integrity of
the protein and different regions of a protein are likely to contribute
in varying ways (with the structural integrity of functionally
essential parts of the protein likely being particularly important in
correct processing).
Herewe identify two regions of hENT1 that are required for correct
localization most likely due to their structural and functional
importance. The PWN (or PYN) triplet is very highly conserved across
ENTs [10] and mutation of W29 has previously been shown to affect
inhibitor sensitivity and nucleoside transport of hENT1 expressed in
yeast [40]. Our ﬁndings also support a role of W29 in function, which
may reﬂect the characteristic of tryptophan or tyrosine aromatic rings
to stack with purine and pyrimidine bases. Taken together these data
support a central role of this motif in function but in addition, here we
highlight the essential role of P28 in maintaining the correct structure
of this region of hENT1 for effective localization at the plasmamembrane in mammalian cells. Given the well-established role of
proline in maintaining protein structure [41], these ﬁndings demon-
strate that structural integrity of hENT1 is essential in effective
processing, localization and therefore function.
Since the C-terminus, like the PWN region, of hENT1 is ultimately
extracellular, the retention seen with truncation of the C-terminus is
unlikely to be due to disruption of targeting/trafﬁcking motifs as
described for other transporters [i.e. 19,21]. Rather, our ﬁndings are
consistent with a role for this region in correct folding or structural
integrity and are consistent with previous observations that demon-
strate that alteration of a single residue within a critical motif or
region of a protein sequence can signiﬁcantly alter protein folding
[42]. The observation of partial retention of the T2 and T4 mutants is
consistent with the observation that some truncated proteins can
escape the ER quality control and still localize to their intended site
[43]. These data also suggest that key motifs possibly involved in
folding (likely the FLF, hydrophobic triplet, motif) lie upstream of the
last 4 amino acids. Indeed, a previous study suggested that truncations
up to 4 amino acids had no effect on the location of hENT1 [35]
suggesting that some truncated mutants can escape processing
checkpoints and ﬁnd their way to the plasma membrane in certain
cell types.
Similarly, we observed that disruption of charge (e.g. non-polar to
lysine) in the hydrophobic triplets at the C-terminus leads to a
disruption in the ability of hENT1 to localize to the plasma membrane
supporting a potential role for the C-terminus in protein folding and
packing of the ﬁnal transmembrane helices (while not speciﬁcally in
targeting to the plasma membrane). It is possible that the phenyla-
lanines in the FLF motif could act as docking sites for protein–protein
interactions as has been seen in the CFTR channel, the gonadotropin-
releasing hormone receptor and the serotonin transporter [44–46].
This is noteworthy since our ﬁndings show that the presence of a
single phenylalanine (plus two hydrophobic partners) is both
necessary and sufﬁcient for correct cell surface expression.
Disruption of the hydrophobicity in this region could then, in turn,
disrupt the interaction of hENT1 with a major ER chaperone such as
BiP, which aids in protein folding through interaction with hydro-
phobic residues [13–15,47]. However, we cannot rule out the
possibility that the introduction of multiple lysines in the FLF region
could cause retention due to the introduction of a di-lysine ER
retention signal [48].
Taken together, our data suggest that, at the C-terminus, hENT1
requires at least one phenylalanine and two hydrophobic residues
followed by a residue that can be positively charged or non-polar and
ﬁnally, a second hydrophobic triplet for effective plasma membrane
localization and transport activity. These data correlate with a
proposed putative tertiary topology of the parasitic ENT1 homolog
(LdNT2) which is based on a computational approach to deﬁning
structure [33]. In this model both the PWN triplet and the C-terminus
(the latter of which has been proposed to lie partially within
transmembrane domain 11) may contribute to the translocation
pore. This model would therefore support the notion that these two
regions play a role in hENT1 function and may explain the reduced
function seen with our plasma membrane localizing mutants (e.g.
mutant D). Furthermore, if the PWN motif and C-terminal region do
indeed line the translocation pore, they could provide a site for
substrate recognition and/or binding.
Our ﬁndings suggest that localization combined with correct
structure dictate overall function of hENT1. Mutations in hENT1, that
potentially affect structural integrity can also impact localization
(presumably due to ER quality control mechanisms) and thus
function. Thus factors involved in correct localization of hENT1 are
complex and cannot simply be narrowed down to a single overly
simpliﬁed amino acid motif. This study provides the basis to further
identify factors such as interacting partners or proteinmotifs involved
in cellular processing, targeting or trafﬁcking of hENT1.
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